Current Research Studies

Cancer – ADVL1312: Phase 1/2 Study of AZD1775 in Combination with Oral Irinotecan in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors

Condition or Therapy:

Solid tumors


Cancer and blood disorders

What is the goal of this study?

The goal of this study is to discover the maximum tolerated dose of adavosertib with irinotecan.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are 1 to 21 years old
  • Have relapsed or refractory solid tumors, neuroblastoma, medulloblastoma or rhabdomysarcoma

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Julie Park